01 — At a Glance
The Chemical Company That Became a Venture Capitalist Overnight
- 52-Week High / Low₹35.8 / ₹19.2
- Q3 FY26 Revenue₹190 Cr
- Q3 FY26 PAT₹30.12 Cr
- Standalone India Revenue (Est.)₹140 Cr
- TTM EPS₹0.85
- Book Value / Share₹6.72
- Price to Book3.24x
- Debt-to-Equity0.00x
- Cash on Hand~₹340 Cr
- ROCE23.8%
Flash Summary: Fineotex just posted Q3 FY26 PAT of ₹30.12 crore — but here’s the kicker: only 15 days of US acquisition contribution happened. Standalone India business is chugging along fine. P/E at 26.1x suggests the market is either betting this company becomes India’s next Pidilite, or is quietly terrified of management’s acquisition appetite. A debt-free balance sheet with ₹340 crore cash means they can do whatever they want next. That’s either exciting or scary depending on your risk appetite.
02 — Introduction
From Textile Mills to Oilfields: The Identity Crisis Nobody Saw Coming
Fineotex Chemical has been around since 1979. For 46 years, they made chemicals for textiles — pretreatment agents, dyeing auxiliaries, finishing products. They were the kind of company that made your expensive shirt softer. You never heard of them. They made no fuss. Life was simple.
Then December 2025 happened. On December 5, Fineotex announced it acquired a 53.33% controlling stake in CrudeChem Technologies Group — a US-based specialty oilfield chemicals manufacturer — for ~$11.5 million. CrudeChem generates ~USD 65 million in annual revenue and supplies friction reducers and advanced chemical fluid additives to oil majors like ExxonMobil, Devon Energy, and NextStar. In simple terms: they went from making fabric soft to making oil wells efficient.
Q3 revenue jumped to ₹190 crore (+46% YoY), but the real story is that only ~₹50 crore of that came from the 15-day contribution of the US acquisition. Strip that out, and the India textile chemicals business is still growing, just at a slower pace because — wait for it — customers faced US tariff headwinds from April to January. Now tariffs are clearing up, and management says they’re rolling back all discounts they gave away. It’s like a restaurant giving free water during a drought, then charging full price once it rains again.
ICRA Rating Note (Feb 2026): Reaffirmed A+ (Positive) / A1+ despite acquisition. ICRA expects the combined entity to maintain healthy credit metrics. The rating agency basically said “we trust that this small-cap chemical maker knows what it’s doing with American oil companies.” Let that sink in.
03 — Business Model: Three Businesses, One Stock
Textile Chemicals, Cleaning Products, and Now… Oilfield Additives?
Fineotex operates in three revenue streams, and after the acquisition, management has essentially made it four. Let’s break down the mess.
Textile Chemicals (~55% of Q3 revenue): Their original and still-dominant business. They supply specialty chemicals for pretreatment, dyeing, printing, and finishing of fabrics. Think of them as the invisible hand that makes your cotton shirt feel premium. They export to 70+ countries and supply to companies like Welspun, Raymond, and Vardhman. In Q3, this business faced headwinds because their customers are heavily dependent on US markets, which faced tariff and clearance issues from April 2025 to January 2026. Management admitted they “became a little bit aggressive in pricing” and rolled back margins to support customers. Now that tariffs have cleared, they’re hiking prices back from March 1.
Cleaning & Hygiene (~15% of Q3 revenue): This is the “failed venture that’s now recovering” business. They make floor cleaners, hand washes, sanitizers, and dishwashing liquids. Q1 and Q2 were disastrous, but Q3 showed improvement. Management credited expanded product range, more salesforce, and bigger account wins. The honest translation: “We threw more bodies at it and it worked.”
Oilfield Specialties (~30% of Q3 revenue): This is CrudeChem, freshly acquired. They make friction reducers, demulsifiers, corrosion inhibitors, and biocides for oil & gas operations. Think of them as the people who make sure your oil well doesn’t become a environmental disaster. Marquee customers include NESR, NextStar, Devon Energy, and ExxonMobil. This is pure margin arbitrage — American rates, proprietary technology, recurring customers.
Water Treatment & Others: Pipeline stage. Management is building relationships in the Middle East and expecting announcements “very near” on water treatment partnerships. Until then, don’t count on it.
Textiles55%of Q3 revenue
Oil & Gas30%of Q3 revenue (CCT)
Hygiene15%of Q3 revenue
Capacity Expansion+80K MTPAfrom CCT acquisition
Strategic Pivot Alert: Management said oil & gas could become 45-50% of revenue in the future. That means textile chemicals — their bread and butter for 46 years — could become a minority business. For investors who bought this stock thinking it was a “textile chemical compounder,” surprise! You’re now a holding company betting on American oilfield chemistry. ICRA gave a Positive outlook because it “believes the company will benefit from acquisitions,” which is financial analyst speak for “we’re optimistic but honestly not sure.”
04 — Financials Overview
Q3 FY26: The Numbers Walk a Tightrope
Result type: Quarterly Results | Q1 FY26 EPS: ₹0.22 | Q2 FY26 EPS: ₹0.22 | Q3 FY26 EPS: ₹0.23 | Avg 9M EPS: ₹0.223 × 4 = ₹0.89 Annualised
| Metric (₹ Cr) |
Q3 FY26
Dec 2025 |
Q3 FY25
Dec 2024 |
Q2 FY26
Sep 2025 |
YoY % |
QoQ % |
| Revenue | 190 | 126 | 138 | +50.8% | +37.7% |
| Less: CrudeChem (15 days) | ~50 | — | — | New | New |
| Organic India Revenue | ~140 | 126 | 138 | +11% | -1.4% |
| Operating Profit | 35 | 27 | 26 | +29.6% | +34.6% |
| OPM % | 18.4% | 21.4% | 18.8% | -300 bps | -40 bps |
| PAT | 30.12 | 20 | 30 | +50.6% | +0.4% |
| EPS (₹) | 0.23 | 0.19 | 0.22 | +21.1% | +4.5% |
The Margin Story: OPM dropped from 21.4% (Q3 FY25) to 18.4% (Q3 FY26). Management blamed two things: (1) CrudeChem has lower EBITDA margins historically (~7-8%), and (2) textile chemicals in India faced pricing pressure due to customer support during tariff crunch. CFO admitted gross margins compressed from 38% to 36%. But here’s the silver lining — management is actively working to improve CCT margins through capital infusion, supplier negotiations, and pricing actions. They promised “double-digit EBITDA margins” at CCT “next coming financial year,” which is manager-speak for “trust us, bro.”
💬 The P/E is 26.1x on a company that’s facing margin compression AND integrating a new acquisition. Is this a “forward-looking growth premium” or are investors pricing in a turnaround story? What’s your take?
05 — Valuation: Fair Value Range
What’s a Small-Cap Chemical Maker Worth After It Becomes an M&A Guy?
